抗PD-1/PD-L1抗体临床治疗不良反应研究进展

Research progress on adverse events in clinical treatment of anti-PD-1/PD-L1 antibodies

尽管抗PD-1/PD-L1抗体已被证实是多种肿瘤的有效治疗手段,但同时也带来了肿瘤免疫治疗所特有的免疫相关不良反应(irAEs)。本文主要就抗PD-1/PD-L1抗体产生的不良反应及其应对方式以及不良反应对患者预后的影响等相关热点问题展开综述。

Although anti-PD-1/PD-L1 antibodies have been proved to be effective for a variety of cancers, meanwhile, it will also bring about immune related adverse events（irAEs）peculiar to tumor immunotherapy. This article mainly reviews the adverse reactions induced by anti-PD-1/PD-L1 antibodies and corresponding countermeasures, as well as the impact of adverse events on the prognosis of patients and other related hot issues.